<< Back to News

FDA Approves TECENTRIQ® (atezolizumab) for first-line (1L) treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).

TECENTRIQ, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).

Tecentriq Patient Assistance & Reimbursement Information:

https://www.tecentriq-hcp.com/small-cell-lung-cancer.html

Full Prescribing Information:

https://www.gene.com/download/pdf/tecentriq_prescribing.pdf